- Home
- LH vs NTRA Comparison
LH vs NTRA Comparison
Compare LH & NTRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LH
- NTRA
- Stock Information
- Founded
- LH 1971
- NTRA 2003
- Country
- LH United States
- NTRA United States
- Employees
- LH N/A
- NTRA N/A
- Industry
- LH Medical Specialities
- NTRA Medical Specialities
- Sector
- LH Health Care
- NTRA Health Care
- Exchange
- LH Nasdaq
- NTRA Nasdaq
- Market Cap
- LH 22.8B
- NTRA 27.0B
- IPO Year
- LH N/A
- NTRA 2015
- Fundamental
- Price
- LH $250.93
- NTRA $199.57
- Analyst Decision
- LH Strong Buy
- NTRA Strong Buy
- Analyst Count
- LH 13
- NTRA 18
- Target Price
- LH $299.00
- NTRA $206.17
- AVG Volume (30 Days)
- LH 874.4K
- NTRA 1.3M
- Earning Date
- LH 10-28-2025
- NTRA 11-06-2025
- Dividend Yield
- LH 1.15%
- NTRA N/A
- EPS Growth
- LH 98.36
- NTRA N/A
- EPS
- LH 10.19
- NTRA N/A
- Revenue
- LH $13,765,300,000.00
- NTRA $2,116,676,000.00
- Revenue This Year
- LH $10.91
- NTRA $25.70
- Revenue Next Year
- LH $4.79
- NTRA $15.42
- P/E Ratio
- LH $24.64
- NTRA N/A
- Revenue Growth
- LH 8.28
- NTRA 38.17
- 52 Week Low
- LH $209.38
- NTRA $125.38
- 52 Week High
- LH $293.72
- NTRA $203.23
- Technical
- Relative Strength Index (RSI)
- LH 35.29
- NTRA 69.72
- Support Level
- LH $248.00
- NTRA $193.29
- Resistance Level
- LH $259.68
- NTRA $203.23
- Average True Range (ATR)
- LH 7.72
- NTRA 7.37
- MACD
- LH -2.67
- NTRA 0.25
- Stochastic Oscillator
- LH 12.47
- NTRA 80.29
About LH Laboratory Corporation of America Holdings
Labcorp is one of the nation's two largest independent clinical laboratories, with roughly 20% of the independent lab market. The company operates approximately 2,000 patient-service centers, offering a broad range of 5,000 clinical lab tests, ranging from routine blood and urine screens to complex oncology and genomic testing.
About NTRA Natera Inc.
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.